New Drugs
Vitamin D metabolites and analogues, diphosphonates, danazol, and bromocriptine COLIN R PATERSON, JOHN FEELY Our understanding of the physiology of vitamin D has been transformed in recent years; one consequence has been the development of analogues which are considerably more potent than vitamin D in the treatment of hypoparathyroidism and of azotaemic osteodystrophy. The treatment of symptomatic patients with Paget's disease of bone has advanced with the establishment of the role of calcitonin and more recently with the introduction of the diphosphonate drugs. Recent experience with bromocriptine confirms its place in the treatment of the prolactinomas, and its list of indications has grown to include parkinsonism and the suppression of lactation. Recently, the medical treatment of endometriosis has advanced with the use of danazol, which may be given to suppress gonadal function.
Vitamin D analogues and metabolites
Vitamin D (calciferol) is now recognised as a precursor for the production by the kidney of a hormone, calcitriol (1,25-dihydroxy-vitamin D,) , responsible for active calcium absorption in the gut. Calcitriol (Rocaltrol) is effective in promoting calcium absorption and raising the plasma calcium in patients whose endogenous calcitriol production is impaired. This is the case in renal failure, in hypoparathyroidism (parathyroid hormone is required for the 1-hydroxylation step in vitamin D metabolism), and in a rare inherited disorder, vitamin D dependent rickets. In these disorders calcitriol is effective in microgram doses compared with the milligram doses needed with native vitamin D.
A useful analogue of calcitriol is alphacalcidol, la-hydroxyvitamin D3 (One-alpha). This is hydroxylated at the 25 position in the liver to give calcitriol as with calcitriol, microgram doses are effective in patients with hypoparathyroidism or with renal failure. Both drugs increase the plasma calcium concentration in a newly diagnosed patient with hypoparathyroidism in a few days.
While the speed of action of calcitriol and alphacalcidol is an advantage compared with that of calciferol itself, this very speed may contribute to the ease with which patients can be poisoned by an unwary physician. As 
Diphosphonates
The diphosphonates are a group of analogues of pyrophosphate, taken by mouth, which inhibit bone resorption and formation. The only diphosphonate presently available is disodium etidronate (Didronel); it is used in Paget's disease to treat bone pain and less commonly neurological complications and immobilisation hypercalcaemia. The optimal dose is between 5 and 10 mg/kg/day. Higher doses (10 to 20 mg/kg/day) cause a more rapid reduction in bone turnover, but side effects -including diarrhoea and bone pain-are troublesome; bone mineralisation is impaired and spontaneous fractures may occur.
Only 5 0o of disodium etidronate is absorbed from the intestine, the remainder being excreted in the faeces. Absorption is impaired by food, particularly foodstuffs containing calcium and antacids, so that the drug is best given once daily while fasting, such as at bedtime. The drug is rapidly removed from the blood by renal excretion and adsorption on to bone surfaces. Increase in plasma phosphate concentrations is common and appears to be harmless.
There is no case for giving diphosphonates (or calcitonin) to symptomless patients with Paget's disease. The patients in whom medical treatment is most clearly indicated are those with bone pain (particularly if plasma alkaline phosphatase activity is appreciably increased) and those with progressive neurological impairment. In some cases it may be difficult to distinguish bone pain due to Paget's disease from that due to osteoarthropathy. In such cases a trial of treatment is appropriate. The diphosphonates should be stopped if the symptoms have not improved within two months.
COMPARISON WITH CALCITONIN
Calcitonin is now available either as the porcine preparation (Calcitare) or as a synthetic salmon calcitonin (Calsynar, Miacalcic). It is considered to be preferable to diphosphonates in the treatment of Paget's disease with recurrent fractures or non-union and also where there are pronounced osteolytic lesions. Calcitonin is more expensive and usually requires-at least initially-daily injections. Flushing occurs after injections in about a quarter of patients. About a quarter of patients develop resistance to treatment, in some as a result of the development of antibodies.
While the overall response to both these agents is similar, one is often effective where the other has failed. A typical course of treatment is for six months, after which with disodium etidronate the patient may remain symptomless for up to two years. Repeated courses may be given if relapse occurs. With calcitonin the period of remission is usually much shorter and maintenance treatment (often 100 IU weekly) is often given. A combination of calcitonin and disodium etidronate has been tried by several workers, but as yet there is no clear evidence that the combination is superior to either alone. Danazol Danazol (Danol) is a synthetic steroid, a derivative of ethisterone, and suppresses the hypothalamic-pituitary-ovarian axis by inhibiting the output of gonadotrophins from the pituitary. In addition, it may act by inhibiting binding of sex steroids to cellular receptors in target tissues and possibly by decreasing the synthesis of sex steroids. It has, therefore, been used to reduce hormonal stimulation to the endometrium and breasts in endometriosis and cystic disease respectively. It is the most effective form of medical treatment for endometriosis in part by temporarily suppressing gonadal function. Side effects are common and predictable in view of its androgenic and anabolic activity.
Danazol is well absorbed with peak concentrations occurring after two hours. It is metabolised in the liver and excreted in bile and urine. Elimination half lives between five and 30 hours have been reported. Like many hormones, however, the half life of its biological activity does not correlate with the plasma half life, and it should be given twice to four times daily.
ENDOMETRIOSIS
When endometriosis is treated with danazol dysmenorrhoea is usually the first symptom to be relieved as menstruation is sup- In men with gynaecomastia danazol has proved valuable in the management of those in whom underlying causes have been excluded. In about two thirds of such patients a dose of 200-600 mg daily relieves the severe and painful symptoms.
Danazol has been tried in precocious puberty, but further experience is needed before its use can be recommended. It has, however, proved effective in preventing attacks in patients with hereditary angioneurotic oedema by increasing the synthesis of the complement (Cl)-esterase inhibitor.
PRECAUTIONS
The successful alleviation of endometriosis and dyspareunia is commonly followed by pregnancy after treatment with danazol has been stopped. Pregnancy should be excluded before danazol is given. Pronounced virilisation of female infants has been reported after the drug has been given to their mothers in pregnancy. It should not be given to patients with impaired cardiac, hepatic, or renal function, and caution is needed in patients with other conditions that may be adversely affected by fluid retention -such as epilepsy and migraine. A firm diagnosis and exclusion of malignant disease, particularly in patients with abnormal uterine bleeding, are essential. Until more is known about the long term effects of this agent, treatment should be for the shortest possible period.
ADVERSE EFFECTS
Many of the adverse effects are androgenic in nature and are reversed after treatment has stopped. Weight gain of 1-4 kg occurs in most patients; other common side effects include acne, seborrhoea, decreased breast size, irregular vaginal bleeding, and mild hirsutism. Muscle cramps affect up to a third of patients and menopausal symptoms, nausea, and rashes occasionally occur. Side effects are largely dose related and are seldom a problem in patients taking only 200 mg daily.
Bromocriptine
Recent experience has firmly established the value of bromocriptine (Parlodel) in various conditions. It is an ergot alkaloid, a derivative of lysergic acid, and acts as a dopamine agonist. Bromocriptine inhibits both basal and stimulated prolactin secretion from the pituitary. It has some less specific dopamine like actions in other areas both in the central nervous system (basal ganglia, vomiting centre) and in blood vessels. These actions underlie the drug's use in Parkinson's disease and also explains some of its common side effects such as nausea and hypotension. Bromocriptine is well absorbed with peak concentrations occurring after two hours. It is almost completely metabolised in the liver and excreted in the bile. The effect of a single dose lasts about six to eight hours. Although its elimination half life is longer, the use of frequent small doses reduces side effects that are associated with high peak concentrations.
INHIBITION OF LACTATION
Given less than 12 hours postpartum bromocriptine prevents the start of lactation, without pain or breast engorgement, and restores prolactin to normal values within 48 hours. It is superior to all other methods of suppressing lactation, including oestrogens, but is considerably more expensive. Unlike oestrogens, it is also very effective in suppressing established lactation and breast engorgement. Bromocriptine (2-5 mg with meals) is usually given twice daily for two weeks; some workers recoimend that this dose should be given once daily for a third week to avoid the recurrence of lactation, which occurs in about a third of patients. Patients should be advised that fertility is rapidly restored. The first ovulation is likely within four weeks of delivery, and suitable contraceptive advice may be needed before the patient leaves hospital.
HYPERPROLACTINAEMIA
Hyperprolactinaemia is an important cause of anovulatory infertility, although the mechanism is not fully understood. A few patients with hyperprolactinaemia also have galactorrhoea. If hyperprolactinaemia due to other causes-for example, drugs such as phenothiazine and methyldopa-is excluded a chromophobe adenoma of the anterior pituitary is the most likely explanation. In women this is commonly a microadenoma and may show no sign of local expansion; in men the usual finding is an adenoma large enough to cause radiological changes and causing low gonadotrophin concentrations, hypogonadism, and infertility.
Bromocriptine (usually 5-7-5 mg daily) rapidly restores prolactin concentrations to normal and ovulatory menstruation returns irrespective of the size of the tumour. In an analysis of infections due to penicillinase-producing strains of Neisseria gonorrhoeae reported in Britain during 1977-81 McCutchan and his coworkers showed that since these strains first appeared cases had doubled annually, primarily as a result of patients infected abroad.' During 1981, however, the number of indigenous cases being reported began to exceed the imported cases, suggesting that the strains had become truly endemic here.
The data for 1982 are summarised in the table. The total for the year was 1033, compared with 433 in 1981. Infection was acquired abroad by 237 patients, 69 more than in the previous year but only 23% of the total, compared with 38% in 1981 and 52% in 1980. Of the 237 patients, 102 had acquired the infection in the Far East (Thailand 51, Philippines 16, Singapore 9, Hong Kong 7), 71 in West Africa (Nigeria 51), and 30 in Europe (West Germany 7, Netherlands 6, Spain 6, France 5). The proportional contribution of these three parts of the world to the total imported infections has changed little in the past three years. The consorts of a further 65 patients were infected abroad.
The infections regarded as indigenous-that is, when both the patient and consort were infected in Britain-show the greatest increase. The total in this category, 519, is 354 more than in 1981. Of these 519 patients, 154 were stated to have contracted the infection in Greater London and a further 157 were reported from laboratories in that area; Birmingham recorded 30 cases, Liverpool 28, Bristol 20, and Leeds 18, and many other areas had smaller numbers of cases. The shift from importation to endemic transmission of penicillinase-producing Neisseria
